Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31139996 | 1.00 | MEN1 (0.39) | MEN1KMT2AALDH1A1KDM4EGLA | |
| SCHEMBL30274950 | 0.88 | NPC1 (0.39) | MEN1KMT2AALDH1A1KDM4EGLA | |
| SCHEMBL22777345 | 0.88 | NPC1 (0.39) | MEN1KMT2AALDH1A1KDM4EGLA | |
| SCHEMBL30490463 | 0.85 | BACE1 (0.35) | GAABACE1MAPT | |
| SCHEMBL25317559 | 0.85 | BACE1 (0.35) | GAABACE1MAPT | |
| SCHEMBL14659247 | 0.83 | ROCK2 (0.39) | MEN1KMT2AALDH1A1KDM4EGLA | |
| SCHEMBL29716250 | 0.78 | POLB (0.47) | MEN1KMT2AALDH1A1KDM4EGAA | |
| SCHEMBL16379424 | 0.77 | RAD51 (0.50) | MEN1KMT2AALDH1A1KDM4EGAA | |
| SCHEMBL14659544 | 0.76 | ALDH1A1 (0.48) | MEN1KMT2AALDH1A1KDM4EGAA | |
| SCHEMBL14659571 | 0.75 | RAB9A (0.41) | MEN1KMT2AALDH1A1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358906-B2 | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors | NOVARTIS AG (CH) | 2025-07-15 | — | — | US | disclosed |
| US-20250163024-A1 | CHEMICAL TARGETING SWI/SNF RELATED, MATRIX ASSOCIATED, ACTIN DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY A, MEMBER 4 (SMARCA4) AND USE IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-05-22 | — | — | US | disclosed |
| EP-4460306-A2 | TARGETING SWI/SNF RELATED, MATRIX ASSOCIATED, ACTIN DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY A, MEMBER 4 (SMARCA4) | Dana-Farber Cancer Institute, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| US-20240270738-A1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | NOVARTIS AG (CH) | 2024-08-15 | — | — | US | disclosed |
| US-11958846-B2 | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors | NOVARTIS AG (CH) | 2024-04-16 | — | — | US | disclosed |
| EP-4219488-A1 | METHOD FOR THE PREPARATION OF UREA COMPOUNDS AS SMARCA2/BRM-ATPASE INHIBITORS | Novartis AG (CH) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023133260-A2 | CHEMICAL TARGETING SWI/SNF RELATED, MATRIX ASSOCIATED, ACTIN DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY A, MEMBER 4 (SMARCA4) AND USE IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133260-A2 | CHEMICAL TARGETING SWI/SNF RELATED, MATRIX ASSOCIATED, ACTIN DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY A, MEMBER 4 (SMARCA4) AND USE IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| EP-3837256-B1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM-ATPASE INHIBITORS | NOVARTIS AG (CH) | 2023-03-08 | — | — | EP | disclosed |
| US-20210323956-A1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | NOVARTIS AG (CH) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958846-B2 | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors | SMARCC1, SMARCC2, SMARCA1 | MEN1 1169/4885KMT2A 394/4885ALDH1A1 2373/4885 |
| US-20250163024-A1 | CHEMICAL TARGETING SWI/SNF RELATED, MATRIX ASSOCIATED, ACTIN DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY A, MEMBER 4 (SMARCA4) AND USE IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) | SMARCE1, SMARCA4, SMARCA2 | MEN1 1691/4885KMT2A 74/4885ALDH1A1 3965/4885 |
| US-20210323956-A1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | SMARCC1, SMARCC2, SMARCA1 | MEN1 1169/4885KMT2A 394/4885ALDH1A1 2373/4885 |
| US-12358906-B2 | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors | SMARCC1, SMARCC2, SMARCA1 | MEN1 1818/4885KMT2A 516/4885ALDH1A1 3060/4885 |
| US-20240270738-A1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | SMARCC1, SMARCC2, SMARCA1 | MEN1 1742/4885KMT2A 514/4885ALDH1A1 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.